The role of carfilzomib in relapsed/refractory multiple myeloma

被引：15
|
作者：
Yee, Andrew J. [1 ]
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Ctr Multiple Myeloma, 55 Fruit St, Boston, MA 02114 USA
来源：
THERAPEUTIC ADVANCES IN HEMATOLOGY | 2021年 / 12卷
关键词：
carfilzomib; multiple myeloma; PROTEASOME INHIBITOR CARFILZOMIB; ONCE-WEEKLY CARFILZOMIB; LOW-DOSE DEXAMETHASONE; RANDOMIZED PHASE-III; SINGLE-AGENT; IRREVERSIBLE INHIBITOR; SURVIVAL ANALYSIS; SAFETY PROFILE; OPEN-LABEL; BORTEZOMIB;
D O I：
10.1177/20406207211019612
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and as a partner in diverse three drug combinations such as with lenalidomide or daratumumab. While it has an established place in relapsed disease, clinicians should be aware of its cardiovascular and renal adverse event profile, which is manageable, in order to optimize outcomes. This review will provide a perspective on the current and future role of carfilzomib in relapsed/refractory multiple myeloma.
引用
收藏
页数：13
相关论文
共 50 条
  • [21] A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China
    Du, Juan
    Fang, Baijun
    Li, Jian
    Jin, Jie
    Wang, Shunqing
    Zou, Dehui
    Cai, Zhen
    Wang, Hongxiang
    Hu, Jianda
    Li, Wei
    Fu, Chengcheng
    Shao, Zonghong
    Xia, Zhongjun
    Liu, Peng
    Niu, Ting
    Tang, En-Tzu
    Kimball, Amy S.
    Hou, Jian
    Chen, Wenming
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 422 - 429
  • [22] Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
    Dubey, A. P.
    Khatri, Sameer
    Maggo, Sachin
    Singh, Nilabh K.
    Sharma, Durgesh
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (06) : 846 - 849
  • [23] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
    Shah, Jatin J.
    Stadtmauer, Edward A.
    Abonour, Rafat
    Cohen, Adam D.
    Bensinger, William I.
    Gasparetto, Cristina
    Kaufman, Jonathan L.
    Lentzsch, Suzanne
    Vogl, Dan T.
    Gomes, Christina L.
    Pascucci, Natalia
    Smith, David D.
    Orlowski, Robert Z.
    Durie, Brian G. M.
    BLOOD, 2015, 126 (20) : 2284 - 2290
  • [24] Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma
    Chari, Ajai
    Larson, Sarah
    Holkova, Beata
    Cornell, Robert F.
    Gasparetto, Cristina
    Karanes, Chatchada
    Matous, Jeffrey V.
    Niesvizky, Ruben
    Valent, Jason
    Lunning, Matthew
    Usmani, Saad Z.
    Anderson, Larry D., Jr.
    Chang, Lipo
    Lee, Yihua
    Pak, Yvonne
    Salman, Zeena
    Graef, Thorsten
    Bilotti, Elizabeth
    Chhabra, Saurabh
    LEUKEMIA & LYMPHOMA, 2018, 59 (11) : 2588 - 2594
  • [25] Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma
    Lendvai, Nikoletta
    Landau, Heather
    Lesokhin, Alexander
    Tsakos, Ioanna
    Koehne, Guenther
    Chung, David
    Devlin, Sean
    Hassoun, Hani
    Giralt, Sergio A.
    BLOOD, 2012, 120 (21)
  • [26] Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma
    Xu, Wenjun
    Sun, Xuedong
    Wang, Baohong
    Guo, Hui
    ANNALS OF HEMATOLOGY, 2018, 97 (02) : 299 - 307
  • [27] The mutational landscape underlying carfilzomib and pomalidomide resistance in relapsed/refractory multiple myeloma
    Xu, Jing
    Giesen, Nicola
    Paramasivam, Nagarajan
    Goldschmidt, Hartmut
    Brors, Benedikt
    Raab, Marc S.
    Weinhold, Niels
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E83 - E84
  • [28] Peripheral Neuropathy Experience in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Carfilzomib
    Martin, Thomas G.
    ONCOLOGY-NEW YORK, 2013, 27 : 4 - 10
  • [29] Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience
    Uysal, Ayse
    Akad Soyer, Nur
    Ozkan, Melda
    Sahin, Fahri
    Vural, Filiz
    Tobu, Mahmut
    Tombuloglu, Murat
    Saydam, Guray
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2018, 48 (01) : 80 - 83
  • [30] Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Yi, Lidan
    Liu, Qiao
    Tan, Chongqing
    Wan, Xiaomin
    Luo, Xia
    Li, Yinbo
    Li, Haiying
    Zeng, Xiaohui
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2024, 17 : 2829 - 2837
12345